Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Jacksonville, Florida 32206


The purpose of this trial is to give a shorter course (5 ½ weeks) of radiation that has as little side effects on normal bladder and rectal tissues as the usual longer course (8 weeks) of radiation, without decreasing the chance of killing prostate cancer cells.

Study summary:

Low Risk - Total of 70 Gy/CGE over 28 treatments Intermediate Risk - Total of 72.5 Gy/CGE over 29 treatments


Inclusion Criteria - Prostate cancer. - Gleason score 2-7. - PSA ≤ 20 ng/ml. Exclusion Criteria: - Previous prostate cancer surgery or pelvic radiation. - Prior or current chemotherapy for prostate cancer. - Active inflammatory bowel disease (Crohn's disease, diverticulitis or ulcerative colitis) affecting the rectum. - History of proximal urethral stricture requiring dilatation. - History of hip replacement. - Diabetes requiring medication. - Prior intrapelvic surgery. - Current and continuing anticoagulation with Warfarin sodium (Coumadin), Clopidogrel bisulfate (Plavix), enoxaparin sodium (Lovenox), or aspirin/er dipyridamole (Aggrenox). - On Flomax (Tamsulosin), Hytrin (Terazosin) or Cardura (Doxazosin), Uroxatral (alfuzosin HCl). - Taking Saw Palmetto or methotrexate and unable or unwilling to discontinue its use during radiation.



Primary Contact:

Principal Investigator
Randal H Henderson, MD
University of Florida

Backup Contact:


Location Contact:

Jacksonville, Florida 32206
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.